Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries [PDF]
Frontiers in Endocrinology, 2023 Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice.
M. Zulf Mughal +13 more
doaj +7 more sources
Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
JBMR Plus, 2022 X‐linked hypophosphatemia (XLH) is a rare genetic disorder that disrupts skeletal and dental mineralization. In addition to rickets in children, XLH patients also have frequent spontaneous dental abscesses that increase the risk of tooth loss and may ...
Margaux Gadion +8 more
doaj +2 more sources
Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report [PDF]
Frontiers in Endocrinology, 2022 IntroductionX-linked hypophosphatemia (XLH) is the most prevalent type of heritable fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets. Recently, anti-FGF23 antibody, burosumab, has become clinically available.
Yuichi Takashi +6 more
doaj +2 more sources
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description [PDF]
Therapeutic Advances in Chronic Disease, 2022 Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH) 2 D) synthesis.
Maria Luisa Brandi +18 more
doaj +12 more sources
Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia [PDF]
Frontiers in EndocrinologyBurosumab, a monoclonal antibody that binds and inhibits FGF23 activity, was approved in 2018 for treatment of children and adults with X-linked hypophosphatemia (XLH), an X-linked dominant disorder due to increased serum fibroblast growth factor 23 ...
Robert Bandir +4 more
doaj +2 more sources
Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking [PDF]
Scientific Reports, 2022 Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH).
Karnpob Kanhasut +5 more
doaj +2 more sources
Burosumab for the Treatment of Tumor-Induced Osteomalacia [PDF]
Journal of Bone and Mineral Research, 2020 ABSTRACT Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a ...
Suzanne M Jan de Beur +11 more
openaire +3 more sources
Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
Bone Reports, 2021 Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a rare disorder caused by somatic mosaicism for the gain of function RAS mutations . Affected patients have segmental epidermal nevi, dysplastic cortical bony lesions, and fibroblast growth factor-23
Manal Khadora, M. Zulf Mughal
doaj +3 more sources
Burosumab prevents further height deficit in toddlers affected by XLH [PDF]
Endocrine ConnectionsBackground: X-linked hypophosphatemia (XLH) is a rare disease caused by PHEX variants. Besides rickets, XLH leads to disproportionately short stature, which develops during the first months of life.
Elisa Sala +9 more
doaj +2 more sources
Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2023 Tumour-induced osteomalacia (TIO) is due to an overproduction of fibroblast growth factor 23 (FGF23) by mesenchymal tumours, causing hypophosphatemia, osteomalacia and muscle weakness.
L Aliberti +4 more
doaj +3 more sources